Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Xiangxue Pharmaceutical Co., Ltd. is actively involved in the full pharmaceutical lifecycle within China, from scientific research and product development to sourcing, production, and market distribution. The company's product portfolio notably includes its branded Xiangxue antivirotic oral liquids. Beyond these pharmaceutical offerings, it also provides a variety of healthcare supplements and comprehensive wellness solutions, such as specialized food and beverage items. Xiangxue Pharmaceutical has forged a strategic alliance with 111, Inc., with the aim of advancing an "Internet + Medicine" framework tailored for China's traditional Chinese medicine industry. The firm was established in 1997 and its main operations are based in Guangzhou, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overvalued on P/FCF.